KR102532713B1 - Novel Saccharomyces cerevisiae strain and use thereof - Google Patents

Abstract

The present invention is a Saccharomyces cerevisiae strain deposited with accession number KCTC14780BP; And to a cosmetic composition, quasi-drug composition, or food composition comprising at least one selected from the group consisting of the strain, culture of the strain, and fermented product of the strain,
Saccharomyces cerevisiae strains, cultures of the strains, fermented products of the strains, or fractions of the cultures or fermented products have excellent skin improvement and soothing effects on sensitive skin, so cosmetic compositions, quasi-drug compositions, and food compositions for skin improvement It is highly usable as a Accordingly, various industrial applications such as cosmetics, quasi-drugs, and food can be expected.

Description

Novel Saccharomyces cerevisiae strain and use thereof {Novel Saccharomyces cerevisiae strain and use thereof}

The present invention is a Saccharomyces cerevisiae strain deposited with accession number KCTC14780BP; And to a cosmetic composition, quasi-drug composition, or food composition comprising at least one selected from the group consisting of the strain, culture of the strain, fermented product of the strain, and fractions of the culture or fermented product.

Cosmetic ingredients are generally known to cause various skin problems such as inflammation, pimples, and swelling (Maibach. H. I., Contact Dermatitis, 6. 369-404,

1980). In addition, various substances used as raw materials for functional cosmetics are also low on the skin.

There are problems with stability or insignificant effects.

For example, retinoids, adenosine, animal placenta-derived proteins, and chlorella extracts are known as cosmetics for improving skin wrinkles and elasticity. Retinol, which is the most widely known, has limitations in usage due to safety issues such as irritation when applied to the skin, and chlorella extract and the like are insignificant, so it is difficult to expect substantial skin elasticity enhancement and wrinkle improvement effects.

Inflammation occurs as a series of defenses aimed at minimizing the response when cells or tissues are damaged by any cause and restoring the damaged area to its original state. It causes swelling, redness, fever, etc., and causes functional disorders. Causes of inflammation include physical factors such as trauma, frostbite, burns, radiation, chemical factors such as acids, and immunological factors such as antibody reactions. do. Dilation of blood vessels occurs by various chemical mediators secreted by cells damaged by external stimuli, and as permeability increases, antibody, complement, plasma, and phagocytic cells flock to the inflammation site. This phenomenon causes erythema.

An anti-inflammatory agent is an agent that acts to remove the inflammatory source and reduce the physiological response and symptoms in order to disappear inflammation. Substances that have been used for anti-inflammatory purposes so far include flufenamic acid, ibuprofen, benzydamine, and indomethacin as non-steroidal agents, and prednisolone as a steroid type. ), dexamethasone, etc., but most of them have problems in terms of safety for the skin or stability when containing cosmetics, so their use is limited.

In general, moisturizing cosmetic compositions used for the skin maintain a certain amount of moisture in human hair or skin to make them look soft and lively, and function to prevent damage such as cracks and dryness. That is, the cosmetic composition for moisturizing the skin is used for the purpose of beautifying the skin or hair and keeping them healthy by supplying a certain amount or more of moisture to the skin or hair or keeping the moisture.

Therefore, in recent years, many studies have been conducted on cosmetic compositions having excellent effects in terms of improving skin conditions or preventing skin aging or skin damage by having excellent skin soothing, regenerating, moisturizing or anti-inflammatory effects.

Under this background, the present inventors have conducted research on raw materials that are safer and have excellent skin improvement effects from natural resources, and the new strain of Saccharomyces cerevisiae discovered this time has a skin improvement effect, and conventional yeast fermentation The present invention was completed by confirming that the skin improvement effect was remarkably superior to that of water.

One object of the present invention is to provide a Saccharomyces cerevisiae strain deposited under accession number KCTC14780BP.

Another object of the present invention is to provide a cosmetic composition for skin improvement containing at least one of the above strain, culture of the strain, fermented product of the strain, and fractions of the culture or fermented product.

Another object of the present invention is to provide a quasi-drug composition for skin improvement containing at least one of the strain, culture of the strain, fermented product of the strain, and fractions of the culture or fermented product.

Another object of the present invention is to provide a food composition for skin improvement containing at least one of the strain, culture of the strain, fermented product of the strain, and fractions of the culture or fermented product.

Another object of the present invention is to provide a method for producing a fermented yeast product, comprising the step of fermenting with a Saccharomyces cerevisiae strain deposited under Accession No. KCTC14780BP.

Another object of the present invention is to cultivate a strain of Saccharomyces cerevisiae deposited with accession number KCTC14780BP; and separating with water, C1 to C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane from the culture or fermented product of the strain, to provide a fraction preparation method.

Hereinafter, the contents of the present invention will be described in detail. On the other hand, the description and embodiment of one aspect disclosed in the present invention can also be applied to the description and embodiment of another aspect with respect to common matters. Additionally, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be seen that the scope of the present invention is limited by the specific descriptions described below.

One aspect of the present invention provides a Saccharomyces cerevisiae strain deposited under accession number KCTC14780BP.

The term of the present invention, "Saccharomyces cerevisiae" refers to a species of yeast belonging to the genus Saccharomyces and Saccharomycetaceae. This species has been widely used since ancient times, playing an important role in winemaking, baking, and brewing. The characteristics of Saccharomyces cerevisiae vary depending on the growth region and natural environmental conditions, so the activity of the strain and its fermented product may vary, and the Saccharomyces cerevisiae of the present invention may be derived from a fermentation broth, but is not limited thereto .

In the present invention, the fermentation broth may be prepared by fermentation for 6 months to 2 years, specifically for 9 months to 1 year and 6 months, and more specifically for 1 year, and the fermentation broth may be a plant fermentation broth, but is not limited thereto.

In one embodiment of the present invention, a fermentation broth was prepared, and it was confirmed that the fermented product of Saccharomyces cerevisiae of the present invention had an excellent skin improvement effect compared to the fermentation product of Saccharomyces cerevisiae, which is a general yeast.

Another aspect of the present invention provides a cosmetic composition for skin improvement comprising at least one of the above strain, culture of the strain, fermented product of the strain, and fractions of the culture or fermented product.

As used herein, the term "strain" refers to a collection of individuals derived from a single cell, propagated through asexual reproduction, and having homogeneous genetic characteristics, and within one species, genetic characteristics Several different strains (genetic variants) exist. In the present invention, the strain refers to Saccharomyces ceviche, and may specifically be Saccharomyces ceviche deposited under accession number KCTC14780BP, but is not limited thereto.

In the present invention, the strain may include cells, dried cells, lysates, and the like of Saccharomyces ceviche. At this time, the dried cells may be spray-dried bacteria, freeze-dried bacteria, vacuum-dried bacteria, drum-dried bacteria, etc., and the lysate is a product obtained by breaking the cell walls of the strain itself by chemical or physical force. can be

The "culture" of the present invention means a product obtained by culturing the strain in a medium. For example, the culture of the present invention may include components remaining in the culture medium of Saccharomyces ceviche after harvesting the strain.

The culture may be a whole culture of the Saccharomyces ceviche strain, a culture supernatant, a lysate, or a fraction thereof. At this time, the culture supernatant can be obtained by centrifuging the culture of the strain, the lysate can be obtained by physically or sonicating the strain, and the fraction is the culture, culture supernatant, lysate, etc. It can be obtained by applying methods such as centrifugation and chromatography.

Any medium and other culture conditions used for culturing the strain of the present invention may be used without particular limitation as long as it is a medium used for the culture of conventional microorganisms of the genus Saccharomyces. Specifically, the strain of the present invention is used as a suitable carbon source and nitrogen source , It can be cultured while controlling temperature, pH, etc. under aerobic or anaerobic conditions in a conventional medium containing phosphorus, inorganic compounds, amino acids and/or vitamins.

Examples of the carbon source in the present invention include carbohydrates such as glucose, fructose, sucrose, and maltose; sugar alcohols such as mannitol and sorbitol; organic acids such as pyruvic acid, lactic acid, citric acid and the like; Amino acids such as glutamate, methionine, lysine, and the like may be included, but are not limited thereto. In addition, natural organic nutritional sources such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sorghum and corn steep liquor can be used, as well as glucose and pasteurized pretreated molasses (i.e., molasses converted to reducing sugars). Carbohydrates such as may be used, and various other carbon sources in appropriate amounts may be used without limitation. These carbon sources may be used alone or in combination of two or more.

Examples of the nitrogen source include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, and ammonium nitrate; Organic nitrogen sources such as amino acids, peptones, NZ-amines, meat extracts, yeast extracts, malt extracts, corn steep liquor, casein hydrolysates, fish or degradation products thereof, defatted soybean cakes or degradation products thereof, and the like can be used. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.

The number of persons may include monopotassium phosphate, dipotassium phosphate, or a sodium-containing salt corresponding thereto. As the inorganic compound, sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, and the like may be used.

In addition, amino acids, vitamins, and/or appropriate precursors may be included in the medium. Specifically, L-amino acids and the like may be added to the culture medium of the strain. Specifically, glycine, glutamate, and/or cysteine may be added, and if necessary, L-amino acids such as lysine may be further added, but it is not necessarily limited thereto. don't

The medium or precursor may be added to the culture in a batch or continuous manner, but is not limited thereto.

In the present invention, the pH of the culture can be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid and the like to the culture in an appropriate manner during cultivation of the strain. In addition, during cultivation, the formation of bubbles can be suppressed by using an antifoaming agent such as a fatty acid polyglycol ester. In addition, in order to maintain the aerobic state of the culture, oxygen or oxygen-containing gas may be injected into the culture, or nitrogen, hydrogen or carbon dioxide gas may be injected without injection of gas or gas to maintain the anaerobic and non-aerobic state.

The temperature of the culture may be 25 °C to 40 °C, more specifically 28 °C to 37 °C, but is not limited thereto. The culturing period may be continued until a desired production amount of a useful substance is obtained, and specifically may be 1 hour to 200 hours, but is not limited thereto.

In the present invention, the term "fermentation" means that microorganisms are not decay reactions during the process of decomposing organic matter using their own enzymes. Fermentation and decay reactions proceed by similar processes, but when useful substances are produced as a result of decomposition, it is called fermentation, and when bad smells or harmful substances are produced, it is called decay.

In the present invention, the method for obtaining the fermented product from the strain is not particularly limited, but the strain is inoculated into a medium, shaken incubated at 20 ° C to 40 ° C for 1 hour to 200 hours, and then the cells are separated by centrifugation, A fermented product can be obtained by a method of disrupting the cells by ultrasonication. Alternatively, it can be obtained according to a method commonly used in the art or similar fields. In the present invention, the type of medium in which the strain is inoculated is not limited as long as the strain can proceed with fermentation.

In the present invention, the fermentation product obtained from the strain is not only the fermented material itself, but also the culture medium of the strain in which the strain and the culture coexist, the fermentation product obtained by filtering the strain from the culture medium, and the strain from the culture medium. A fermented product obtained by filtering it, an extract obtained by extracting the fermented product or a culture medium containing the same, a diluted solution obtained by diluting the fermented product or its extract, a dried product obtained by drying the fermented product or its extract, and a cell body of the strain collected and crushed Lysates, etc., include all kinds of materials including fermented products generated from the above strains.

As used herein, the term "fraction" refers to a product obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various components.

In the present invention, the fractionation method for obtaining the fraction is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include a method of obtaining a fraction from the extract by treating the extract obtained by extracting the culture or fermentation product of the strain with a predetermined solvent.

In the present invention, the type of solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more. In the case of using an alcohol among the fractionation solvents, C1 to C4 alcohols may be preferably used.

In the present invention, the fraction may include a polypeptide extracted from a culture or fermentation product of a strain.

In the present invention, a peptide refers to a polymer in which amino acid units are artificially or naturally linked, and is a substance in which two or more amino acids are linked, and is referred to as a tripeptide, an oligopeptide, or a polypeptide according to the number of amino acids. Specifically, in the present invention, a polypeptide (polypeptide) may mean one containing 100 or more amino acids, but is not limited thereto.

In the present invention, "polypeptide extracted from a culture or fermentation product of a strain" means that a culture or fermentation product is obtained from a strain and then a peptide aggregate or polypeptide having a certain size or more having a functionality in the culture or fermentation product is isolated do. In the present invention, "polypeptide extracted from a culture or fermentation product of a strain" is used interchangeably with the terms "yeast polypeptide" or "fraction".

In the present invention, the method of separating the fractions from the fermented product is not particularly limited, but only the supernatant is filtered through concentration and precipitation (solvent, centrifugation process) from the lysate disrupted using the cells obtained by fermenting the strain, followed by spray drying fractions can be obtained.

The term of the present invention, "skin improvement" means skin moisturizing, skin soothing, skin regeneration, skin inflammation improvement, wrinkle improvement, elasticity improvement, skin whitening, antioxidant, anti-aging, skin protection from external stimuli, sensitive skin soothing, sensitive skin improvement , It may be any one or more selected from the group consisting of erythema relief, itching relief, skin barrier function enhancement, skin irritation relief, and skin pain relief, but is not limited thereto.

As used herein, the term "improvement" refers to any activity that at least reduces a parameter related to alleviation or treatment of a condition, for example, the severity of a symptom, and includes skin moisturizing, skin soothing, skin regeneration, skin inflammation improvement, wrinkle improvement, Includes all of one or more of elasticity improvement, skin whitening, antioxidant, anti-aging, skin protection from external stimuli, sensitive skin soothing, sensitive skin improvement, erythema relief, itching relief, skin barrier function enhancement, skin irritation relief, and skin pain relief can do.

The skin improvement is cell activity enhancement, NO production inhibition, hyaluronic acid production promotion, collagen synthesis promotion, melanin expression inhibition, free radical scavenging, PGE2 (Prostaglandin E2) expression inhibition, LOR (Loricrin) expression increase, TNF-a expression inhibition, or It may be achieved through the effect of inhibiting TRPV1 activity, but is not limited thereto.

Specifically, the present inventors confirmed that the fermented product of Saccharomyces cerevisiae KCTC14780BP and/or the yeast polypeptide had an excellent skin improvement effect compared to the fermented product of general yeast. More specifically, the fermented product and/or yeast polypeptide of KCTC14780BP in Saccharomyces cerevisiae promote cell activity, inhibit NO production, promote hyaluronic acid synthesis, promote collagen synthesis, inhibit melanin expression, scavenge free radicals, inhibit PGE2 expression, It was confirmed that the effect of increasing LOR expression, inhibiting TNF-a expression, or inhibiting TRPV1 activity was excellent. Therefore, compared to the fermented product and/or yeast polypeptide of Saccharomyces cerevisiae of the present invention, compared to general yeast or its fermented product, skin soothing, skin regeneration, skin inflammation improvement, skin moisturizing, wrinkle improvement, elasticity improvement, skin whitening, Antioxidation, anti-aging, skin protection from external stimuli, sensitive skin soothing, sensitive skin improvement, erythema relief, itching relief, skin barrier function enhancement, skin irritation relief, and skin improvement effects such as skin pain relief were confirmed to be excellent.

As used herein, the term "regeneration" refers to suppressing deterioration of functions of cells, tissues, or organs or recovering degraded functions. Deterioration of cell, tissue, or organ function may result from cell, tissue, or organ damage. Such damage may be caused by various factors such as radiation therapy, drug therapy, surgery, infection, inflammation, degenerative disease, autoimmune disease, and aging. Meanwhile, the regeneration may be achieved by promoting cell differentiation, but is not limited thereto. "Skin regeneration" in the present invention means restoring the damaged part of the skin tissue again. Skin regeneration in the present invention may be due to cell activity enhancement, but is not limited thereto.

In one embodiment of the present invention, while there was no effect on cell activity in the normal yeast fermented product, it was confirmed that the cell activity rate was remarkably high in the yeast (Saccharomyces cerevisiae KCTC14780BP) fermented product and / or yeast polypeptide of the present invention. (Table 2).

As used herein, the term "skin soothing" refers to relieving and calming erythema, itching, irritated skin, or sensitive skin areas, and may include skin irritation relief. Examples include, but are not limited to, relieving skin itching, relieving skin pain, reducing skin water loss, and/or reducing redness.

As used herein, "inflammation" is a kind of in vivo response to damage or infection of a specific tissue, and the main mediator is immune cells. The purpose of such inflammation is to suppress tissue damage as much as possible, remove infectious agents, and regenerate tissue. In the present invention, skin soothing and regeneration may be due to inhibition of NO production, but is not limited thereto.

The term "NO (nitric oxide, nitrous acid)" of the present invention plays various roles such as removing bacteria and tumors, regulating blood pressure, or mediating nerve transmission, but when an inflammatory reaction occurs, iNOS (inducible nitric oxide) synthase) is increased to produce a large amount of NO, and the excessively produced NO causes tissue damage, gene mutation, nerve damage, etc., and increases vascular permeability to promote inflammatory reactions such as edema. While NO production is increased in inflamed cells, NO production is suppressed when the skin is calmed, so there is an essential correlation between them.

In one embodiment of the present invention, the NO production inhibition ability was also excellent in the yeast fermented product and / or yeast polypeptide of the present invention compared to the general yeast fermented product, confirming the skin soothing and inflammation improvement effect (Table 3).

As used herein, the term "moisturizing the skin" refers to all actions that maintain a smooth surface by supplying moisture to the skin or blocking evaporation of moisture to maintain the flexibility of the skin and inducing uniform exfoliation of dead skin cells, and "drying" means a condition in which such skin moisturizing is not sufficient. The skin moisturizing effect can help improve wrinkles and increase elasticity of the skin. Specifically, skin moisturizing may be due to promotion of hyaluronic acid production, but is not limited thereto.

As used herein, the term "hyaluronic acid" is a type of glycosaminoglycans, and refers to a chain-like polymeric polysaccharide material in which glucuronic acid and N-acetylglucosamine residues are repeatedly linked. Hyaluronic acid can contain water equivalent to 300 to 1000 times its own weight, and exhibits a moisturizing effect on the skin by combining with moisture.

In one embodiment of the present invention, it was confirmed that the fermentation product and / or yeast polypeptide of the present invention, Saccharomyces cerevisiae, has an excellent rate of hyaluronic acid synthesis enhancement, through which the yeast fermentation product and / or yeast polypeptide Significant effects such as skin moisturizing were confirmed (Table 4).

The term "wrinkles" of the present invention can be largely divided into expression wrinkles caused by expression muscles used to make facial expressions and fine wrinkles caused by general or local skin decline. Specifically, wrinkles may be caused by genes, reduction of collagen and elastic fibers present in the skin dermis, external environment, and the like. For the purpose of the present invention, wrinkles may be used as a meaning including both facial expression wrinkles and fine wrinkles, but is not limited thereto.

As used herein, the term "elasticity" refers to a force that holds the skin taut when pressed with a finger, and "elasticity improvement" or "elasticity enhancement" means enhancing the elasticity of the skin by strengthening the subcutaneous fat layer structure of the subject. It may mean increasing the elasticity of the skin by using the composition of the invention.

The term of the present invention, "aging" refers to a phenomenon in which biological structures and functions decline with the passage of time, and the anti-aging of the present invention is not limited to the extent of aging, such as preventing, suppressing, or delaying aging. don't Wrinkle improvement and anti-aging in the present invention may be due to the promotion of collagen synthesis, but is not limited thereto.

The term of the present invention, "collagen" is a fibrous protein found in most animals, especially mammals, and occupies most of all connective tissues in the body, such as skin and cartilage, and fibroblasts, which are the most common cells in the body. (fibroblasts) produce and secrete collagen. Gelatine, which is widely used in cooking or in the food and pharmaceutical industries, is an irreversible hydrolysis of collagen. Since the decrease in collagen causes wrinkles and is the main cause of reducing skin elasticity, synthesis of collagen is essential for improving wrinkles and enhancing elasticity.

In one embodiment of the present invention, it was confirmed that the fermented product and/or yeast polypeptide of Saccharomyces cerevisiae, the yeast of the present invention, had an excellent rate of collagen synthesis enhancement, and through this, the yeast fermented product and/or yeast polypeptide Significant effects such as wrinkle improvement and elasticity enhancement were confirmed (Table 5).

In the present invention, the term "whitening" refers to a method of increasing the brightness of skin whose brightness is reduced due to excessive pigments such as melanin or maintaining the brightness of the skin at a certain level, skin with increased brightness formed by the above method, etc. As a comprehensive meaning, it may specifically mean skin whitening. The "skin whitening" may be understood as an improvement in symptoms caused by an increase in melanin, such as melasma and freckles, as melanin production is inhibited as tyrosinase activity is inhibited.

In one embodiment of the present invention, when the yeast (Saccharomyces cerevisiae KCTC14780BP) fermented product and / or yeast polypeptide treatment of the present invention, the melanin production inhibition rate was excellent, thereby confirming the skin whitening effect (Table 6)

In the present invention, the term "antioxidation" means to include all actions to inhibit oxidation, and may specifically mean an action to remove free radicals such as reactive oxygen species, but is not limited thereto. Active oxygen oxidizes and destroys cells in the body, and thus is exposed to various diseases. In addition, since a complex antioxidant defense network is developed in the skin to protect against reactive oxygen species, antioxidant can be associated with the effect of “protecting the skin from external stimuli”.

As used herein, the term "anti-aging" means suppressing or alleviating the progress of aging. Cellular aging means cell oxidation, and proper maintenance of active oxygen can be treated as a major principle in preventing cell oxidation and cell aging.

In one embodiment of the present invention, when the yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and / or yeast polypeptide treatment of the present invention is excellent in free radical (active oxygen) scavenging effect, antioxidant, anti-aging and external stimulation The skin protection effect was confirmed from (Table 7)

As used herein, the term "sensitive skin" refers to skin that reacts more sensitively than normal skin to external irritants, allergic substances, or environmental changes or internal causes of the human body, and thus easily causes irritation or dermatitis. It refers to complaints of various skin reactions such as erythema (redness), dead skin cells, and blisters, and subjective symptoms such as itching, stinging, irritation, pain, and burning due to external stimuli such as cosmetics and internal causes such as hormonal changes.

In one embodiment of the present invention, when the yeast (Saccharomyces cerevisiae KCTC14780BP) fermented product and / or yeast polypeptide treatment of the present invention inhibits the expression of erythema / itch inducing factor (PGE2), the main component of the skin barrier, LOR (Loricrin ) Increased expression, inhibition of inflammatory cytokine (TNF-a) expression, and cutaneous nerve stimulation inducer (TRPV1) activity, alleviating erythema/itching, irritation/pain, which are typical symptoms of sensitive skin, and strengthening the skin barrier By doing so, it was confirmed that there is a soothing and / or improving effect on sensitive skin (Tables 8 to 11)

The term "cosmetic composition" as used herein refers to solutions, external ointments, creams, foams, nourishing lotions, softening lotions, perfumes, packs, softening waters, emulsions, makeup bases, essences, soaps, liquid cleansers, bath additives, sunscreen creams, It may be a formulation selected from the group consisting of sun oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray. , but not limited thereto.

The cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and as typical ingredients, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners, A chelating agent, a colorant, a preservative, a flavoring agent, and the like may be suitably blended, but is not limited thereto.

Cosmetically acceptable carriers included in the cosmetic composition of the present invention vary according to the formulation of the cosmetic composition.

When the cosmetic formulation of the present invention is an ointment, paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanthate, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, oxide as a carrier component Zinc or the like may be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil and the like may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan may be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a suspension, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc. may be used as carrier components. It may be, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, and in particular, in the case of a spray, chloro propellants such as fluorohydrocarbons, propane/butane or dimethyl ether.

On the other hand, all of the ingredients described in the present invention may preferably be included in the composition of the present invention within the range of not exceeding the maximum value specified in the regulations on cosmetic safety standards and China's 'cosmetic safety and technical regulations'.

Another aspect of the present invention provides a quasi-drug composition for skin improvement comprising at least one of the strain, culture of the strain, fermented product of the strain, and fractions of the culture or fermented product.

"Saccharomyces cerevisiae", "strain", "culture", "ferment", "fraction", "yeast polypeptide", "skin improvement", "improvement", "regeneration", "skin soothing" ", "Inflammation", "NO", "Moisturizing skin", "Hyaluronic acid", "Wrinkles", "Elasticity", "Aging", "Collagen", "Whitening", "Antioxidation", "Protect skin from external stimuli ", "anti-aging" and "sensitive skin" are as described above.

The term "quasi-drugs" of the present invention refers to body cleansers, disinfectant cleaners, detergents, kitchen cleaners, cleaning cleaners, toothpaste, gargles, wet wipes, detergents, soaps, hand washes, hair cleaners, hair softeners, humidifier fillers, masks, ointments, and filters It may be selected from the group consisting of fillers, but is not limited thereto.

The quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent as needed in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, aromatics, preservatives, and the like. can include

Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, gum acacia, alginate, calcium phosphate, calcium Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil , injectable esters, Witepsol, Macrogol, Tween 61, cacao butter, laurage, and the like.

When the culture of the strain of the present invention, its fermented product, or a fraction of the cultured or fermented product is used as a quasi-drug, it may additionally contain one or more active ingredients exhibiting the same or similar functions. For example, it may include known skin beneficial bacteria enhancement, skin harmful bacteria suppression, skin soothing, skin inflammation improvement, skin whitening, skin regeneration, and wound healing components. When additional wrinkle improvement, skin whitening, skin trouble improvement, and skin moisturizing ingredients are included, the skin soothing, skin regeneration, skin inflammation improvement, and skin moisturizing effects of the composition of the present invention can be further increased. When adding the above components, skin safety according to combined use, ease of formulation, and stability of active ingredients may be considered.

The quasi-drug composition of the present invention is a skin moisturizing ingredient known in the art, retinoic acid, TGF, animal placenta-derived protein, betulinic acid and chlorella extract; As anti-inflammatory components known in the art, non-steroidal flufenamic acid, ibuprofen, benzidamine, indomethacin, prednisolone, dexamethasone, allantoin, azene, hydrocortisone; And it may further include one or two or more components selected from the group consisting of derivatives thereof and various plant extracts. Additional components may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition, and the content range is skin safety, the strain of the present invention, the culture of the strain, the fermentation product, or the fraction extracted from the fermentation product of the strain. It may be adjusted according to requirements such as ease of formulation.

Formulation method, dosage, usage method, components, etc. of quasi-drugs can be appropriately selected from conventional techniques known in the art.

Another aspect of the present invention provides a food composition for skin improvement comprising at least one of the above strain, culture of the strain, fermented product of the strain, and fractions of the culture or fermented product.

"Saccharomyces cerevisiae", "strain", "culture", "ferment", "fraction", "yeast polypeptide", "skin improvement", "improvement", "regeneration", "skin soothing" ", "inflammation", "NO", "skin moisturizing", "hyaluronic acid", "wrinkles", "elasticity", "aging", "collagen", "whitening", "antioxidation", "protects skin from external stimuli ", "anti-aging" and "sensitive skin" are as described above.

The term "food" of the invention means meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamins Saccharomyces cerevisiae, which includes all foods in the usual sense such as complexes and health functional foods, deposited under the accession number KCTC14780BP of the present invention, the culture of the strain, the fermentation product of the strain, and As long as it can include the fraction of the culture or fermentation, it is not limited thereto. In addition, it can be prepared by adding the strain according to the present invention, the culture of the strain, the fermented product of the strain, and the juice, tea, jelly, juice, etc. prepared by using the culture or fermented fraction as a main component. , powders, granules, tablets, tablets, capsules, or liquids.

The health functional food (functional food) is the same term as food for special health use (FoSHU), and is a medicine processed to efficiently display bioregulatory functions in addition to nutritional supply, and has high medical effect. means food. Here, "function (sex)" means to obtain useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions. The food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and ingredients commonly added in the art during the preparation. In addition, the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food. The composition for food of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of using food as a raw material and free from side effects that may occur when taking drugs for a long time, and has excellent portability. Of the foods can be consumed as supplements to enhance the immune-enhancing effect.

The health food (health food) means a food that has an active health maintenance or promotion effect compared to general food, health supplement food (health supplement food) means a food for the purpose of health supplement. In some cases, the terms health functional food, health food, and health supplement food are used interchangeably.

Specifically, the health functional food is Saccharomyces cerevisiae deposited under Accession No. KCTC14780BP, a culture of the strain, a fermentation product of the strain, and a beverage of any one or more of the fractions of the culture or fermentation , Tea, spice, chewing gum, confectionery, etc., or added to food materials, or encapsulated, powdered, suspended, etc. It means that when ingested, it brings a specific effect on health, but unlike general medicines, food As a raw material, it has the advantage of not having side effects that can occur when taking drugs for a long time.

The composition may further include a physiologically acceptable carrier. The type of carrier is not particularly limited, and any carrier commonly used in the art may be used.

In addition, the composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, and visual properties. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chrome (Cr) may be included. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be included.

In addition, the composition contains preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder and high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxy toluene (BHT), etc.), coloring agents (tar colorant, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclemate, saccharin, Sodium, etc.), flavorings (vanillin, lactones, etc.), expanding agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (thickeners), coating agents, gum base agents, foam inhibitors, solvents, food additives such as improvers (food additives) may be included. The additive may be selected according to the type of food and used in an appropriate amount.

Saccharomyces cerevisiae deposited under the accession number KCTC14780BP, a culture of the strain, a fermented product of the strain, and a fraction of the culture or fermented product are added as they are or other food or food It can be used together with the ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). In general, the food composition of the present invention may be added in an amount of 50 parts by weight or less, specifically 20 parts by weight or less, based on the food or beverage when preparing food or beverage. However, when ingested for a long period of time for health and hygiene purposes, the amount below the above range may be included, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

An example of the food composition of the present invention may be used as a health beverage composition, and in this case, as in conventional beverages, various flavoring agents or natural carbohydrates may be included as additional components. The aforementioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrins and cyclodextrins; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol. Sweeteners include natural sweeteners such as thaumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame may be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

In addition to the above, the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, It may contain alcohol or a carbonating agent, and the like. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages, or vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Specifically, Saccharomyces cerevisiae deposited with accession number KCTC14780BP, the culture of the strain, the fermented product of the strain, and the culture or fermented fraction of any one or more of 0.00001 to 0.00001 to the total weight of the food composition It may contain 100% by weight.

Another aspect of the present invention provides a yeast fermented product manufacturing method comprising the step of fermenting with a Saccharomyces cerevisiae strain deposited under Accession No. KCTC14780BP.

The "Saccharomyces cerevisiae", "strain", and "fermented product" are as described above.

Another aspect of the present invention is culturing a strain of Saccharomyces cerevisiae deposited with accession number KCTC14780BP; and separating with water, C1 to C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane in the culture or fermentation product of the strain, and providing a method for preparing the fraction.

The "Saccharomyces cerevisiae", "strain" and "fraction" are as described above.

Since the Saccharomyces cerevisiae strain, the culture of the strain, the fermented product of the strain, or the fraction of the cultured or fermented product of the present invention has excellent skin improvement and soothing effects on sensitive skin, a cosmetic composition for skin improvement, a quasi-drug composition And the utilization as a food composition is high. Accordingly, various industrial applications such as cosmetics, quasi-drugs, and food can be expected.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited to these examples.

Example 1. Isolation of yeast (KCTC14780BP in Saccharomyces cerevisiae) strain

A novel yeast strain, Saccharomyces cerevisiae CF2-0w-22, was obtained from the plant fermentation broth fermented for one year.

The Saccharomyces cerevisiae CF2-0w-22 strain was deposited with the Korea Institute of Bioscience and Biotechnology (KCTC), an entrusted institution under the Budapest Treaty, on November 16, 2021, and was given accession number KCTC14780BP. The strain was confirmed to have the 18s rRNA nucleotide sequence of SEQ ID NO: 1.

Example 2. Preparation of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and polypeptides extracted from the yeast fermentation product

Example 2-1. Yeast (Saccharomyces cerevisiae KCTC14780BP) Preparation of fermented product

Saccharomyces cerevisiae KCTC14780BP strain was inoculated into the medium, and the cells were separated by centrifugation after shaking culture. After suspending the cells in purified water, the cells were disrupted by ultrasonication, and finally, KCTC14780BP fermented product of Saccharomyces cerevisiae was prepared. Specific conditions and configurations are shown in Table 1 below.

Strain Saccharomyces cerevisiae KCTC14780BP Sonication Amplitude 40, Process time 40 min, Pulse-ON time 1 S, Plus-OFF time 2 S Concentration of KCTC14780BP culture extract in Saccharomyces cerevisiae 5%

Example 2-2. Yeast (Saccharomyces cerevisiae KCTC14780BP) Preparation of Polypeptide Extracted from Fermentation and Fractions Containing It

Saccharomyces cerevisiae KCTC14780BP strain was inoculated into the medium and cultured with shaking, and after separating the cells through centrifugation, the lysate was obtained and concentrated. Thereafter, the lysate was suspended in alcohol twice the content and centrifuged to separate the precipitated Polypeptide fraction from the lysate to prepare a fraction containing the KCTC14780BP polypeptide in the yeast of the present invention, Saccharomyces cerevisiae.

Example 3. Yeast (Saccharomyces cerevisiae KCTC14780BP) fermented product and fraction containing yeast polypeptide confirmed cell activity enhancing effect

Human dermal fibroblast samples were treated for 48 hours at each concentration. Cell activity was measured using the CCK-8 kit method. The cell activity efficacy of the sample was calculated and measured in comparison with the negative control (DMEM containing 0% serum).

In order to confirm the cell activity enhancing effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermented product and yeast polypeptide-containing fractions, general cells, normal cells were treated with FBS, Saccharomyces cerevisiae KCTC14780BP fermented product treated, general Cell activity rates were compared when the yeast (Saccharomyces cerevisiae KCTC 7296) fermented product and the yeast (Saccharomyces cerevisiae KCTC14780BP)-containing fraction were treated (Table 2).

sample Cell activity rate (% of control) Normal cells (negative control) 0 normal cells + FBS (positive control, 5%) 17.55 Normal Yeast Fermentation (1%) No effect (-10.89) Saccharomyces cerevisiae KCTC14780BP fermented product (1%) 20.15 Saccharomyces cerevisiae Fraction containing KCTC14780BP polypeptide (0.1%) 60.76

As shown in the results of Table 2, it was confirmed that the cell activity rate increased when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing the yeast (KCTC14780BP in Saccharomyces cerevisiae) polypeptide. At this time, the increase rate of the fraction containing the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide was better than that of the normal yeast fermentation product prepared under the same conditions.

Accordingly, it was found that the fraction containing the fermented product of KCTC14780BP and yeast polypeptides in Saccharomyces cerevisiae of the present invention exhibits excellent effects on cell activity and the like.

Example 4. Confirmation of yeast (Saccharomyces cerevisiae KCTC14780BP) fermented product and fraction containing yeast polypeptides for skin soothing and inflammation improvement (inhibition of NO production)

Raw 264.7 cells were diluted for each concentration, treated with 1 μg/ml of LPS, and cultured for 24 hours. The NO production inhibitory ability was evaluated as follows using the NO quantification kit method.

NO production inhibition ability (%) = (1-(NO production amount when sample is added / NO production amount when sample is not added) x 100

sample NO production inhibition ability (% of control) Normal cells (negative control) 0 Normal cells + L-NMMA (positive control, 20ug/mL) 47.9 plain yeast Fermentation (0.01%) 18.4 Saccharomyces cerevisiae KCTC14780BP fermented product (0.01%) 37.8 Fraction containing KCTC14780BP polypeptide in Saccharomyces cerevisiae (0.0001%) 31.3

As shown in the results of Table 3, it was confirmed that the NO production inhibition ability increased when normal cells were treated with the fraction containing the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide. At this time, the increase rate of the fermented product of Saccharomyces cerevisiae KCTC14780BP was better than that of the normal yeast fermented product prepared under the same conditions.

Accordingly, it was found that the fraction containing the fermented product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide of the present invention exhibits excellent effects on skin soothing and inflammation improvement.

Example 5. Yeast (Saccharomyces cerevisiae KCTC14780BP) Confirmation of hyaluronic acid synthesis enhancing effect of fermented product

Human keratinocyte HaCaT samples were treated for 72 hours at each concentration. Hyaluronic acid synthesis was compared with the control group (DMEM treatment containing 0% serum) using Quantikine ELISA Hyaluronan from R&D Systems to quantify the moisturizing ability (Table 4).

sample Hyaluronic acid synthesis rate (% of control) Normal cells (negative control) 0 Normal cells + Retinoic acid (positive control, 1ppm) 17.8 Normal Yeast Fermentation (1%) 12.6 Saccharomyces cerevisiae KCTC14780BP fermented product (1%) 93.8

As shown in the results of Table 4, it was confirmed that the hyaluronic acid synthesis rate increased when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP. At this time, the hyaluronic acid synthesis rate of KCTC14780BP fermented with Saccharomyces cerevisiae was superior to that of normal yeast fermented under the same conditions.

Accordingly, it was found that the fermented product of Saccharomyces cerevisiae KCTC14780BP of the present invention exhibits excellent effects on moisturizing and soothing the skin.

Example 6. Yeast (Saccharomyces cerevisiae KCTC14780BP) fermented product and fraction containing yeast polypeptide confirm collagen synthesis enhancement effect

Human dermal fibroblast samples were treated for 48 hours at each concentration. The collagen synthesis rate was measured using the procollagen type I C-peptide (PIP) EIA kit method. The collagen synthesis efficacy of the sample was calculated and measured in comparison with the negative control group (DMEM containing 0% serum).

In order to confirm the collagen synthesis enhancement effect of the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide, normal cells, TGF-β treatment in normal cells, treatment of KCTC14780BP fermentation product in Saccharomyces cerevisiae, yeast poly Collagen synthesis rates were compared when treating fractions containing peptides (Table 5).

sample Collagen synthesis rate (% of control) Normal cells (negative control) 0 Normal cells + TGF-β (positive control, 10ng/ml) 23.92 Fractions containing normal yeast fermentation (1%) 9.81 Saccharomyces cerevisiae KCTC14780BP fermented product (1%) 16.38 Saccharomyces cerevisiae Fraction containing KCTC14780BP polypeptide (0.01%) 16.99

As shown in the results of Table 5, it was confirmed that the collagen synthesis rate increased when normal cells were treated with the fraction containing the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide. At this time, compared to the normal yeast fermentation product prepared under the same conditions, the collagen synthesis rate of the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing the yeast polypeptide was superior.

Accordingly, it was found that the fraction containing the fermented product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide of the present invention exhibits excellent effects on skin wrinkle improvement and elasticity enhancement.

Example 7. Yeast (KCTC14780BP in Saccharomyces cerevisiae) Confirmation of melanin expression inhibitory effect of fermented products and fractions containing yeast polypeptides

Samples were diluted for each concentration in B16f10 melanocytes, treated for 72 hours, cultured, and then the amount of melanin pigment present in melanocytes was quantified. After calculating the melanin production inhibition rate relative to the total protein amount, the DMSO control group (serum 0% containing DMEM, untreated group, negative control group) was calculated as a standard % as 100% and the value was measured.

In order to measure the degree of decrease in the amount of melanin pigment in the fraction containing the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide, a positive control group (Arbutin 200 ppm (Lim YJ et al., 2009, Arch Pharm Res.) ), Saccharomyces cerevisiae KCTC14780BP fermented product treatment, and fractions containing yeast polypeptides were compared for inhibition of melanin production (Table 6).

sample Treatment concentration (%) Inhibition of melanin production (%) Positive control (Arbutin) 0.02 56.4 Saccharomyces cerevisiae KCTC14780BP fermented product 0.01 34.6 Fraction containing KCTC14780BP polypeptide from Saccharomyces cerevisiae 0.01 33.7 0.001 33

As shown in the results of Table 6, it was confirmed that the melanin production inhibition rate increased when normal cells were treated with the fraction containing the fermented product of Saccharomyces cerevisiae KCTC14780BP) and the yeast polypeptide.

Accordingly, it was found that the fraction containing the fermented product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide of the present invention exhibits an excellent effect on skin whitening.

Example 8. Confirmation of free radical scavenging effect of yeast (KCTC14780BP in Saccharomyces cerevisiae) fermented product and fraction containing yeast polypeptide

After dissolving the sample in DMSO, equal amounts (100 μl) of 0.15 mM DPPH solution and the sample were mixed and reacted at room temperature for 30 minutes. Then, the absorbance (A540) at 540 nm was measured for the color change of DPPH.

To evaluate the radical scavenging ability of KCTC14780BP fermented product in Saccharomyces cerevisiae and a fraction containing yeast polypeptide, positive control (Vitamin C), treatment with KCTC14780BP fermented product in Saccharomyces cerevisiae, treatment with fraction containing yeast polypeptide The radical scavenging ability was compared by obtaining the IC50 value through the measurement of the A540 value at the time (Table 7).

sample IC 50 (%) positive control
(Vitamin C) 0.000606±0.00006 Saccharomyces cerevisiae KCTC14780BP fermented product 3.476±0.337 Fraction containing KCTC14780BP polypeptide from Saccharomyces cerevisiae 0.1804±0.0174

As shown in the results of Table 7, the free radical (active oxygen) scavenging effect was confirmed when normal cells were treated with the fraction containing the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the yeast polypeptide.

Accordingly, it was found that the fermented product of Saccharomyces cerevisiae KCTC14780BP of the present invention has excellent antioxidant, anti-aging and skin protection effects from external stimuli.

Example 9. Confirmation of the soothing effect on sensitive skin of a fraction containing yeast polypeptides of yeast (Saccharomyces cerevisiae KCTC14780BP)

Example 9-1. Confirmation of the inhibitory effect of the erythema/pruritus-inducing factor (PGE2) expression of the fraction containing the yeast polypeptide

Raw 264.7 cells were diluted for each concentration and cultured for 24 hours with UVB (11mJ) treated samples. The PGE2 (Prostaglandin E2) production inhibitory ability (%) was evaluated using the PGE2 quantification kit method. Specifically, a standard curve was prepared using 4PL regression, and the PGE2 production effect induced by UVB was calculated as 100%, and the amount of PGE2 produced during sample treatment was calculated and the value was measured (Table 8).

sample Treatment concentration (%) PGE2 generation (%) Control (UVB) 11 mJ 100 Fraction containing KCTC14780BP polypeptide from Saccharomyces cerevisiae 0.1 67.5 0.001 87.6

As shown in the results of Table 8, the effect of inhibiting the expression of PGE2 was confirmed when normal cells were treated with the fraction containing the KCTC14780BP polypeptide of Saccharomyces cerevisiae.

Accordingly, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects such as relieving skin erythema/itching and soothing and improving sensitive skin.

Example 9-2. Confirmation of the effect of increasing the expression of LOR (Loricrin), a major ingredient for strengthening the skin barrier, of fractions containing yeast polypeptides

After treating HaCaT cells with TNF-a (10 pg/ml) for 3 hours, samples were diluted for each concentration, mixed with TNF-a-treated HaCaT cells, and cultured for 24 hours. The degree of increase in the expression of LOR (Loricrin), a major component of the skin barrier, was quantified using qPCR (Table 9).

sample Treatment concentration (%) LOR gene expression
(Relative mRNA level, of control) untreated group - One Control (TNF-a) 10 pg/ml 0.39 Fraction containing KCTC14780BP polypeptide from Saccharomyces cerevisiae 0.1 0.52

As shown in the results of Table 9, it was confirmed that LOR expression increased when normal cells were treated with the fraction containing the KCTC14780BP polypeptide in Saccharomyces cerevisiae.

Accordingly, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects such as strengthening the skin barrier and soothing and improving sensitive skin.

Example 9-3. Confirmation of inflammatory cytokine inhibitory effect of fractions containing yeast polypeptides

HaCaT cells were diluted for each concentration and cultured for 24 hours with UVB (11mJ) treated samples. The expression level of an inflammatory cytokine (TNF-a) found in sensitive skin was calculated using qPCR and the value was measured (Table 10).

sample Treatment concentration (%) TNFa gene expression
(Relative mRNA level, of control) untreated group - One Control (UVB) 11 mJ 3.25 Fraction containing KCTC14780BP polypeptide from Saccharomyces cerevisiae 0.1 2.09 0.01 2.05

As shown in the results of Table 10, it was confirmed that TNF-a expression was suppressed when normal cells were treated with the fraction containing the KCTC14780BP polypeptide of Saccharomyces cerevisiae.

Accordingly, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects such as soothing and improving sensitive skin.

Example 9-4. Confirmation of the inhibitory effect of TRPV1 activity, a factor that induces cutaneous nerve stimulation, of fractions containing yeast polypeptides

HEK 293T-TRPV1 cells were treated with diluted samples for each concentration, and after 10 minutes, the inhibitory effect on transient receptor potential vanilloid-1 (TRPV1) activity was evaluated using a calcium influx detection assay kit (Table 11).

sample Treatment concentration (%) TRPV1 activity
(RFU, relative fluorescent unit) untreated group - 83.57 Negative control (Capsaicin)
*Induction of TRPV1 activity 10uM 101.86 Positive control (Capsazepin)
*Inhibiting TRPV1 activity 3uM 75.91 Fraction containing KCTC14780BP polypeptide from Saccharomyces cerevisiae 0.1 75.68 0.01 75.83

As shown in the results of Table 11, it was confirmed that TRPV1 activity was inhibited when normal cells were treated with the fraction containing the KCTC14780BP polypeptide of Saccharomyces cerevisiae. At this time, it was confirmed that the TRPV1 activity inhibitory effect was superior to that of the positive control group treated under the same conditions.

Accordingly, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects such as reduction of skin nerve irritation/pain, soothing and improvement of sensitive skin, and the like.

From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention may be embodied in other specific forms without changing its technical spirit or essential features. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not limiting. The scope of the present invention should include all changes or modifications derived from the meaning and scope of the claims to be described later and their equivalent concepts rather than the detailed description above.

Korea Research Institute of Bioscience and Biotechnology KCTC14780BP 20211116

Claims (14)

As a Saccharomyces cerevisiae strain deposited with accession number KCTC14780BP,
The strain has the characteristics of skin soothing and skin inflammation improvement.
A cosmetic composition for skin improvement comprising at least one of the strain of claim 1, a culture of the strain, a fermented product of the strain, and a fraction of the cultured or fermented product.
A cosmetic composition for soothing or improving sensitive skin comprising a fraction of the fermented strain of claim 1.
The method of claim 2, wherein the skin improvement consists of skin regeneration, skin moisturizing, wrinkle improvement, elasticity improvement, skin whitening, antioxidant, anti-aging, sensitive skin soothing, sensitive skin improvement, erythema relief, itching relief, and skin barrier function enhancement. A cosmetic composition that further has at least one or more characteristics selected from the group.
The cosmetic composition of claim 2, wherein the cosmetic composition promotes cell activity, inhibits NO production, promotes hyaluronic acid synthesis, promotes collagen synthesis, inhibits melanin expression, scavenges free radicals, inhibits PGE2 (Prostaglandin E2) expression, increases LOR (Loricrin) expression, and TNF -a A cosmetic composition that has an expression inhibitory or TRPV1 activity inhibitory effect.
The cosmetic composition according to claim 2, wherein the fraction is fractionated with water, C1 to C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane in the culture or fermentation of the strain.
A quasi-drug composition for skin improvement comprising at least one of the strain of claim 1, a culture of the strain, a fermented product of the strain, and a fraction of the cultured or fermented product.
The method of claim 7, wherein the skin improvement consists of skin regeneration, skin moisturizing, wrinkle improvement, elasticity improvement, skin whitening, antioxidant, anti-aging, sensitive skin soothing, sensitive skin improvement, erythema relief, itching relief, and skin barrier function enhancement. Which further has any one or more characteristics selected from the group, quasi-drug composition.
The quasi-drug composition according to claim 7, wherein the quasi-drug composition promotes cell activity, inhibits NO production, promotes hyaluronic acid synthesis, promotes collagen synthesis, inhibits melanin expression, scavenges free radicals, inhibits PGE2 (Prostaglandin E2) expression, increases LOR (Loricrin) expression, A quasi-drug composition having an effect of inhibiting TNF-a expression or TRPV1 activity.
A food composition for skin improvement comprising at least one of the strain of claim 1, a culture of the strain, a fermented product of the strain, and a fraction of the cultured or fermented product.
The method of claim 10, wherein the skin improvement is skin soothing, skin regeneration, skin inflammation improvement, skin moisturizing, wrinkle improvement, elasticity improvement, skin whitening, antioxidant, anti-aging, sensitive skin soothing, sensitive skin improvement, erythema relief, itching relief And further having any one or more characteristics selected from the group consisting of enhancing skin barrier function, the food composition.
The method of claim 10, wherein the food composition promotes cell activity, inhibits NO production, promotes hyaluronic acid synthesis, promotes collagen synthesis, inhibits melanin expression, scavenges free radicals, inhibits PGE2 (Prostaglandin E2) expression, increases LOR (Loricrin) expression, A food composition having an effect of inhibiting TNF-a expression or inhibiting TRPV1 activity.
A method for producing a fermented product comprising the step of fermenting with a Saccharomyces cerevisiae strain deposited under accession number KCTC14780BP.
Cultivating a strain of Saccharomyces cerevisiae deposited under accession number KCTC14780BP; and
A method for producing a fraction comprising the step of separating water, C1 to C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane from a culture or fermentation product of the strain.